Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation

Swetha Kambhampati(Johns Hopkins University), Charalambos Andreadis(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Bradley D. Hunter(Intermountain Healthcare), Chiung‐Yu Huang, Thomas Martin(University of California, San Francisco), Andrei Varnavski(Adaptive Biotechnologies (United States)), Bita Fakhri(University of California, San Francisco), Miguel Hernandez Pampaloni(University of California, San Francisco)
Clinical Lymphoma Myeloma & Leukemia
November 11, 2020
10.1016/j.clml.2020.11.005
Cited by 3

Related Papers

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523